Therapeutic effects of stem cells and substrate reduction in juvenile Sandhoff mice

Neurochemical Research

Volumn 37, Issue 6, 2012, Pages 1335-1343

  Arthur, J R ^a   Lee, J P ^b   Snyder, E Y ^b   Seyfried, T N ^a  

^a BOSTON COLLEGE   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

Gangliosides; Sandhoff disease; Stem cell; Substrate reduction therapy

Indexed keywords

ASIALO GANGLIOSIDE GM2; BETA GALACTOSIDASE; BETA N ACETYLHEXOSAMINIDASE; GANGLIOSIDE GM2; IMINOSUGAR; N BUTYLDEOXYGALACTONOJIRIMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL COMPOSITION; BRAIN CORTEX; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENGRAFTMENT; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; JUVENILE ANIMAL; MALE; MOUSE; NEURAL STEM CELL; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; SANDHOFF DISEASE; SHAM PROCEDURE; STEM CELL TRANSPLANTATION; THERAPY EFFECT;

1-DEOXYNOJIRIMYCIN; ANIMALS; BETA-N-ACETYLHEXOSAMINIDASES; G(M2) GANGLIOSIDE; HEXOSAMINIDASE B; MICE; NEURAL STEM CELLS; SANDHOFF DISEASE;

MUS;

EID: 84862893298     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-012-0718-0     Document Type: Article

References (55)

1. Jeyakumar M, Butters TD, Dwek RA et al (2002) Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis. Neuropathol Appl Neurobiol 28:343-357 (Pubitemid 35279069)
2. Jeyakumar M, Thomas R, Elliot-Smith E et al (2003) Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 126:974-987 (Pubitemid 36372994)
3. Kyrkanides S, Miller AW, Miller JN et al (2008) Peripheral blood mononuclear cell infiltration and neuroinflammation in the HexB-/-mouse model of neurodegeneration. J Neuroimmunol 203:50-57
4. Baek RC, Kasperzyk JL, Platt FM et al (2008) N- butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. Neurochem Int 52:1125-1133
5. Sango K, Yamanaka S, Hoffmann A et al (1995) Mouse models of tay-sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet 11:170-176
6. Phaneuf D, Wakamatsu N, Huang JQ et al (1996) Dramatically different phenotypes in mouse models of human tay-sachs and Sandhoff diseases. Hum Mol Genet 5:1-14 (Pubitemid 26018268)
7. Platt FM, Neises GR, Reinkensmeier G et al (1997) Prevention of lysosomal storage in tay-sachs mice treated with N-butyldeoxynojirimycin. Science 276:428-431 (Pubitemid 27180707)
8. Jeyakumar M, Butters TD, Cortina-Borja M et al (1999) Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci USA 96:6388-6393 (Pubitemid 29256675)
9. Ranes MK, El-Abbadi M, Manfredi MG et al (2001) N-butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours. Br J Cancer 84:1107-1114 (Pubitemid 32448510)
10. Platt FM, Jeyakumar M, Andersson U et al (2003) Substrate reduction therapy in mouse models of the glycosphingolipidoses. Philos Trans R Soc Lond B Biol Sci 358:947-954 (Pubitemid 36639719)
11. Andersson U, Smith D, Jeyakumar M et al (2004) Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiol Dis 16:506-515 (Pubitemid 38942983)
12. Kasperzyk JL, El-Abbadi MM, Hauser EC et al (2004) N- butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis. J Neurochem 89:645-653 (Pubitemid 38534150)
13. Kasperzyk JL, d'Azzo A, Platt FM et al (2005) Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice. J Lipid Res 46:744-751 (Pubitemid 43073284)
14. Platt FM, Jeyakumar M, Andersson U et al (2005) New developments in treating glycosphingolipid storage diseases. Adv Exp Med Biol 564:117-126
15. Denny CA, Kasperzyk JL, Gorham KN et al (2006) Influence of caloric restriction on motor behavior, longevity, and brain lipid composition in Sandhoff disease mice. J Neurosci Res 83:1028-1038
16. Elliot-Smith E, Speak AO, Lloyd-Evans E et al (2008) Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis. Mol Genet Metab 94:204-211
17. Platt FM, Jeyakumar M (2008) Substrate reduction therapy. Acta Paediatr Suppl 97:88-93 (Pubitemid 351421298)
18. Wortmann SB, Lefeber DJ, Dekomien G et al (2009) Substrate deprivation therapy in juvenile Sandhoff disease. J Inherit Metab, Dis
19. Denny CA, Heinecke KA, Kim YP et al (2010) Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice. J Neurochem 113:1525-1535
20. Andersson U, Butters TD, Dwek RA et al (2000) N- butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol 59:821-829 (Pubitemid 30081705)
21. Ichikawa S, Hirabayashi Y (1998) Glucosylceramide synthase and glycosphingolipid synthesis. Trends Cell Biol 8:198-202 (Pubitemid 28188114)
22. Platt FM, Jeyakumar M, Andersson U et al (2001) Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis 24:275-290 (Pubitemid 32479421)
23. Cox TM, Aerts JM, Andria G et al (2003) The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) gaucher disease: a position statement. J Inherit Metab Dis 26:513-526 (Pubitemid 37321530)
24. Jeyakumar M, Smith DA, Williams IM et al (2004) NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann Neurol 56:642-649 (Pubitemid 39540744)
25. Jeyakumar M, Norflus F, Tifft CJ et al (2001) Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood 97:327-329 (Pubitemid 32061278)
26. Lee JP, Jeyakumar M, Gonzalez R et al (2007) Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med 13:439-447 (Pubitemid 46559825)
27. Jeyakumar M, Lee JP, Sibson NR et al (2009) Neural stem cell transplantation benefits a monogenic neurometabolic disorder during the symptomatic phase of disease. Stem Cells 27:2362-2370
28. Takamiya K, Yamamoto A, Furukawa K et al (1996) Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc Natl Acad Sci USA 93:10662-10667 (Pubitemid 26333045)
29. Sheikh KA, Sun J, Liu Y et al (1999) Mice lacking complex gangliosides develop wallerian degeneration and myelination defects. Proc Natl Acad Sci USA 96:7532-7537 (Pubitemid 29299696)
30. Chiavegatto S, Sun J, Nelson RJ et al (2000) A functional role for complex gangliosides: motor deficits in GM2/GD2 synthase knockout mice. Exp Neurol 166:227-234
31. Yamashita T, Wu YP, Sandhoff R et al (2005) Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions. Proc Natl Acad Sci USA 102:2725-2730 (Pubitemid 40299860)
32. Yu RK, Yen SI (1975) Gangliosides in developing mouse brain myelin. J Neurochem 25:229-232
33. Seyfried TN, Miyazawa N, Yu RK (1983) Cellular localization of gangliosides in the developing mouse cerebellum: analysis using the weaver mutant. J Neurochem 41:491-505 (Pubitemid 13030573)
34. Seyfried TN (1987) Ganglioside abnormalities associated with failed neural differentiation in a T-locus mutant mouse embryo. Dev Biol 123:286-291
35. Yu RK, Macala LJ, Taki T et al (1988) Developmental changes in ganglioside composition and synthesis in embryonic rat brain. J Neurochem 50:1825-1829
36. Arthur JR, Lee JP, Snyder EY et al (2010) Therapeutic effects of stem cells and substrate reduction in Sandhoff mice. In: American society for neurochemistry 41st annual meeting, p 27, Abstract PTW06-12
37. Galjaard H (1979) Early diagnosis and prevention of genetic disease. Ann Clin Biochem 16:343-353 (Pubitemid 10105218)
38. Hauser EC, Kasperzyk JL, d'Azzo A et al (2004) Inheritance of lysosomal acid beta-galactosidase activity and gangliosides in crosses of DBA/2J and knockout mice. Biochem Genet 42:241-257 (Pubitemid 39012266)
39. Parker MA, Anderson JK, Corliss DA et al (2005) Expression profile of an operationally-defined neural stem cell clone. Exp Neurol 194:320-332 (Pubitemid 40966992)
40. Macala LJ, Yu RK, Ando S (1983) Analysis of brain lipids by high performance thin-layer chromatography and densitometry. J Lipid Res 24:1243-1250 (Pubitemid 14236574)
41. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226:497-509
42. Seyfried TN, Ando S, Yu RK (1978) Isolation and characterization of human liver hematoside. J Lipid Res 19:538-543 (Pubitemid 8395749)
43. Svennerholm L (1957) Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method. Biochim Biophys Acta 24:604-611
44. Ando S, Chang NC, Yu RK (1978) High-performance thin-layer chromatography and densitometric determination of brain ganglioside compositions of several species. Anal Biochem 89:437-450 (Pubitemid 9067266)
45. Snyder EY, Deitcher DL, Walsh C et al (1992) Multipotent neural cell lines can engraft and participate in development of mouse cerebellum. Cell 68:33-51
46. Snyder EY, Taylor RM, Wolfe JH (1995) Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature 374:367-370
47. Snyder EY, Park KI, Flax JD et al (1997) Potential of neural "stem-like" cells for gene therapy and repair of the degenerating central nervous system. Adv Neurol 72:121-132
48. Yandava BD, Billinghurst LL, Snyder EY (1999) "Global" cell replacement is feasible via neural stem cell transplantation: evidence from the dysmyelinated shiverer mouse brain. Proc Natl Acad Sci USA 96:7029-7034 (Pubitemid 29275004)
49. Aboody KS, Brown A, Rainov NG et al (2000) Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 97:12846-12851
50. Muller FJ, Snyder EY, Loring JF (2006) Gene therapy: can neural stem cells deliver? Nat Rev Neurosci 7:75-84 (Pubitemid 41828933)
51. Guillaume DJ, Huhn SL, Selden NR et al (2008) Cellular therapy for childhood neurodegenerative disease. Part I: rationale and preclinical studies. Neurosurg Focus 24:E22
52. Selden NR, Guillaume DJ, Steiner RD et al (2008) Cellular therapy for childhood neurodegenerative disease. Part II: clinical trial design and implementation. Neurosurg Focus 24:E23
53. Lindvall O, Kokaia Z (2010) Stem cells in human neurodegenerative disorders - time for clinical translation? J Clin Invest 120:29-40
54. Schwarz SC, Schwarz J (2010) Translation of stem cell therapy for neurological diseases. Transl Res 156:155-160
55. Kohan R, Cismondi IA, Oller-Ramirez AM et al (2011) Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses. Curr Pharm Biotechnol 12:867-883